Theraclone makes good on $10.6M VC financing plan

Theraclone Sciences' acting CEO Steven Gillis is backing up what he told FierceBiotech recently about his firm's financing plans. The Seattle-based biotech, which was just named a 2011 Fierce 15 company, has tacked on $10.6 million to its Series B round of financing with the support of previous backers.

The upstart plans to put the money into moving ahead with its I-Star platform that enables the firm to quickly identify human antibodies that can serve as therapies against cancer, infectious diseases and other illnesses, according to the company. Gillis, a managing director at ARCH Venture Partners, has told us that the financing would provide a cash cushion for the permanent chief executive the firm hopes to recruit.

"The anticipated near-term initiation of Theraclone's first clinical trial and our discovery collaboration with Pfizer earlier this year are important milestones that demonstrate Theraclone's continued progress with our R&D pipeline and technology platform," Gillis said in a statement. "The continued support from our investors represents both a vote of confidence and an ability to sustain our rapid pace of activity and progress."

The latest cash infusion brings the 6-year-old biotech's second-round financing to $41 million, and it included contributions from ARCH, Alexandria Real Estate Equities, Amgen Ventures, Canaan Partners, Healthcare Ventures and Zenyaku Kogyo.

- here's the release

Special Report: FierceBiotech's 2011 Fierce 15

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.